In vivo, however, while the deletion of CXCR4 in AML MLL-AF9+ HSPCs prolonged leukemic mouse survival, deletion of CXCL12 within the AML microenvironment did not alter the development and progression of the disease (166). Here, CXCR4 is linked to acute myeloid leukemia.